<DOC>
	<DOCNO>NCT00307827</DOCNO>
	<brief_summary>The purpose study ass efficacy , immunogenicity , safety various dos visilizumab subject intravenous steroid-refractory ulcerative colitis ( IVSR-UC ) evaluate optimal dosing .</brief_summary>
	<brief_title>Study Visilizumab Subjects With Intravenous Steroid-Refractory Ulcerative Colitis ( IVSR-UC )</brief_title>
	<detailed_description>PDL BioPharma , Inc. formerly know Protein Design Labs , Inc .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Inclusion Criteria Eligible subject consider inclusion study meet follow criterion : Males female , 18 year age old . Diagnosis ulcerative colitis ( UC ) , verify endoscopy perform within 60 month prior consent . Severe active disease , define modify Truelove Witts severity index ( MTWSI ) &gt; = 11 consent , confirmatory MTWSI &gt; = 10 fifth consecutive day intravenous ( IV ) steroid within 1 day prior randomization . Mayo score &gt; = 10 Mayo mucosal subscore &gt; = 2 minimum 3 consecutive day ( ie , fourth consecutive day ) IV steroid . Adequate contraception day consent 3 month last dose study drug . Negative serum pregnancy test screening . Negative Clostridium difficile test within 10 day prior randomization . Signed date informed consent Health Insurance Portability Accountability Act ( HIPAA ) applicable . Exclusion Criteria Subjects ineligible study meet one follow criterion : UC require immediate intervention . History total proctocolectomy , subtotal colectomy ileorectal anastomosis Presence ileostomy . White blood cell count le 2.5 x 10^3/mcL ; platelet count le 150 x 10^3/mcL ; hemoglobin level less 8 g/dL . Active medically significant infection , particularly viral etiology , eg , know cytomegalovirus ( CMV ) colitis . This include incidence medically significant opportunistic infection within past 12 month . Live vaccination within 6 week prior randomization . Significant organ dysfunction , include cardiac , renal , liver , central nervous system ( CNS ) , pulmonary , vascular , gastrointestinal , endocrine , laboratory abnormality . History treatment lymphoproliferative disorder ( LPD ) malignancy within past 5 year ( exclude nonmelanoma skin cancer carcinoma situ cervix ) . Seropositivity infection human immunodeficiency virus ( HIV1 ) , hepatitis B virus ( HBV ) surface antigen , hepatitis C virus ( HCV ) . Pregnancy nursing . Treatment first dose infliximab another antiTNFa drug within 4 week randomization , treatment subsequent dose antiTNFa drug within 2 week randomization . Treatment cyclosporine tacrolimus ( FK506 ) within 2 week prior randomization . Treatment investigational drug therapy within 60 day prior randomization , except mention two exclusion criterion . Unwilling unable discontinue UC drug , except glucocorticoid oral 5ASA , immediately prior randomization . Nontherapeutic level chronic antiseizure medication subject prior history seizure . Any condition , investigator 's opinion , make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Steroid-Refractory</keyword>
	<keyword>IVSR-UC</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>